Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.45 |
| ▸ | FNTB | P49356 | 13/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 11/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463248 | 0.97 | FOLH1 (0.46) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL30463274 | 0.97 | FOLH1 (0.46) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL29428964 | 0.97 | FOLH1 (0.46) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL31279889 | 0.94 | FNTA (0.47) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL3928619 | 0.94 | FNTA (0.47) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL29660264 | 0.94 | GNPAT (0.45) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL30168010 | 0.93 | SIRT5 (0.48) | SIRT5IL23R | |
| SCHEMBL31157701 | 0.92 | BACE1 (0.45) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL31157745 | 0.92 | FOLH1 (0.45) | FNTAFNTBPGGT1BSIRT5GNPAT | |
| SCHEMBL30998021 | 0.91 | SIRT5 (0.53) | SIRT5GNPATFOLH1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190616-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190616-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | GLA, ALG3, ANXA6 | FNTA 3091/4885FNTB 4413/4885PGGT1B 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.